THPB-Containing Herbal Preparations for the Treatment of Drug Abuse

用于治疗药物滥用的含有 THPB 的草药制剂

基本信息

  • 批准号:
    7661335
  • 负责人:
  • 金额:
    $ 22.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Despite intense research efforts, drug addiction persists as a serious public health problem for which no effective treatment exists. Although they are likely beneficial, traditional herbal preparations are not widely considered to be viable options for the management of drug addiction, due in part to the paucity of clinical and preclinical studies examining their efficacy and safety. Recent studies by our research team and others have demonstrated that the tetrahydroprotoberberine (THPB) alkaloid, levo-tetrahydropalmatine (l-THP), isolated from crushed roots of the herb Stephania delavayi Diels (di bu long) may be useful for treating drug addiction. THPBs are naturally occurring alkaloids found in plants from the botanical genera Corydalis and Stephania and are contained in many traditional Chinese herbal preparations. Two of these species, Corydalis ambigua (yan hu suo) and Stephania tetranda (fang ji) are among the 50 fundamental herbs in Chinese herbology and have been used for their sedative, neuroleptic and analgesic properties. Several THPBs, most notably l-THP and the levo isomer of stepholidine (l-SPD) have pharmacological profiles that make them ideally suited for treating drug addiction, including antagonist and/or partial agonist effects at a variety of dopamine (DA) receptors. Further characterization of the effectiveness of THPBs in preclinical models of drug abuse should facilitate our understanding of which THPB-containing preparations will have the greatest utility for treating drug-dependent populations. This proposal builds on preliminary data demonstrating that l-THP reduces cocaine-seeking behavior in preclinical rat models and that l-THP reduces drug craving and relapse in recovering heroin addicts. The two isolated THPB constituents selected for testing (l-THP and l-SPD) have distinct properties that may make them safer and more effective compared to existing DA receptor antagonist drugs. The proposed studies will use preclinical rat self-administration based procedures to compare the effects of l-THP and l-SPD with those of the non-selective DA receptor antagonist, fluphenazine, and an "atypical" anti- psychotic in paradigms designed to examine the ability of these agents, when administered acutely or chronically, to curb cocaine use and to prevent the relapse of cocaine seeking induced by drug re-exposure, the onset of stress, and exposure to drug-associated conditioned cues. The occurrence of potential undesirable effects as a consequence of chronic administration of these compounds, including sedation, extrapyramidal symptoms, weight gain abuse liability, and hepatotoxicity will also be examined. It is anticipated that, through preclinical investigation of the effectiveness and safety of isolated THPBs, we will be able to advance the use of herbal preparations containing these THPBs as viable treatments for drug addiction.
描述(由申请人提供):尽管进行了大量的研究工作,但药物成瘾仍然是一个严重的公共卫生问题,没有有效的治疗方法。虽然它们可能是有益的,但传统的草药制剂并没有被广泛认为是管理药物成瘾的可行选择,部分原因是缺乏临床和临床前研究来检查其疗效和安全性。我们的研究团队和其他人最近的研究表明,从草药Stephania delavayi Diels(di bu long)的粉碎根中分离出的四氢原小檗碱(THPB)生物碱左旋四氢巴马汀(L-THP)可能有助于治疗药物成瘾。THPB是天然存在的生物碱,存在于植物属Cortophila和Stephania的植物中,并包含在许多传统的中草药制剂中。其中两个物种,Corpus ambigua(yan hu suo)和Stephania tetranda(fang ji)是中国草药学中的50种基本草药之一,并因其镇静,神经安定和止痛特性而被使用。几种THPB,最值得注意的是l-THP和千金藤啶的左旋异构体(l-SPD)具有药理学特性,使得它们理想地适合于治疗药物成瘾,包括对多种多巴胺(DA)受体的拮抗剂和/或部分激动剂作用。进一步表征THPB在药物滥用临床前模型中的有效性,应有助于我们了解哪种含THPB的制剂对治疗药物依赖人群具有最大的效用。该建议建立在初步数据的基础上,这些数据表明,l-THP减少了临床前大鼠模型中的可卡因寻求行为,并且l-THP减少了恢复海洛因成瘾者的药物渴望和复发。选择用于测试的两种分离的THPB成分(l-THP和l-SPD)具有不同的性质,这可能使它们与现有的DA受体拮抗剂药物相比更安全和更有效。所提出的研究将使用基于临床前大鼠自我给药的程序来比较l-THP和l-SPD与非选择性DA受体拮抗剂氟奋乃静和“非典型”抗精神病药的作用,所述方法设计成检查这些药剂在急性或慢性给药时抑制可卡因使用和预防由药物再暴露诱导的可卡因寻求复发的能力,压力的发作,以及暴露于与药物相关的条件暗示。还将检查这些化合物长期给药导致的潜在不良反应的发生情况,包括镇静、锥体外系症状、体重增加滥用倾向和肝毒性。预计通过对分离的THPB的有效性和安全性的临床前研究,我们将能够推进使用含有这些THPB的草药制剂作为药物成瘾的可行治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John R. Mantsch其他文献

Aversion-induced dopamine reductions predict drug-taking and escape behaviors
厌恶诱导的多巴胺减少预测吸毒和逃避行为
  • DOI:
    10.1038/s41386-025-02101-7
  • 发表时间:
    2025-04-09
  • 期刊:
  • 影响因子:
    7.100
  • 作者:
    Elaine M. Grafelman;Bridgitte E. Côté;Lisa Vlach;Ella Geise;G. Nino Padula;Daniel S. Wheeler;Matthew C. Hearing;John R. Mantsch;Robert A. Wheeler
  • 通讯作者:
    Robert A. Wheeler
A Computational Approach to Analyzing Spatiotemporal Trends in Gun Violence and Mental Health Disparities among Racialized Communities in US Metropolitan Areas
Glucocorticoid–endocannabinoid interactions in the prelimbic cortex mediate stress-potentiated reinstatement of cocaine seeking
  • DOI:
    10.1016/j.drugalcdep.2014.09.470
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jayme R. McReynolds;Oliver Vranjkovic;Evan N. Graf;Cecilia J. Hillard;John R. Mantsch
  • 通讯作者:
    John R. Mantsch
Concomitant adrenal hormonal stress responses are required for cocaine-induced locomotor sensitization
  • DOI:
    10.1016/j.drugalcdep.2014.09.553
  • 发表时间:
    2015-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    David F. Pena;Lisa M. Keller;Conor B. Masterson;Eric J. Cottor;John R. Mantsch
  • 通讯作者:
    John R. Mantsch

John R. Mantsch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John R. Mantsch', 18)}}的其他基金

Aversion signals in the reward system
奖励系统中的厌恶信号
  • 批准号:
    10570985
  • 财政年份:
    2019
  • 资助金额:
    $ 22.35万
  • 项目类别:
Aversion signals in the reward system
奖励系统中的厌恶信号
  • 批准号:
    9906889
  • 财政年份:
    2019
  • 资助金额:
    $ 22.35万
  • 项目类别:
Aversion signals in the reward system
奖励系统中的厌恶信号
  • 批准号:
    10357863
  • 财政年份:
    2019
  • 资助金额:
    $ 22.35万
  • 项目类别:
THPB-Containing Herbal Preparations for the Treatment of Drug Abuse
用于治疗药物滥用的含有 THPB 的草药制剂
  • 批准号:
    7783842
  • 财政年份:
    2009
  • 资助金额:
    $ 22.35万
  • 项目类别:
THPB-Containing Herbal Preparations for the Treatment of Drug Abuse
用于治疗药物滥用的含有 THPB 的草药制剂
  • 批准号:
    7839349
  • 财政年份:
    2009
  • 资助金额:
    $ 22.35万
  • 项目类别:
Stress response and HPA regulation in cocaine addiction
可卡因成瘾中的应激反应和 HPA 调节
  • 批准号:
    6560344
  • 财政年份:
    2002
  • 资助金额:
    $ 22.35万
  • 项目类别:
GCs, CRF and Stressor-Induced Relapse
GC、CRF 和压力源诱发的复发
  • 批准号:
    8212440
  • 财政年份:
    2002
  • 资助金额:
    $ 22.35万
  • 项目类别:
GCs, CRF and Stressor-Induced Relapse
GC、CRF 和压力源诱发的复发
  • 批准号:
    7791278
  • 财政年份:
    2002
  • 资助金额:
    $ 22.35万
  • 项目类别:
Stress response and HPA regulation in cocaine addiction
可卡因成瘾中的应激反应和 HPA 调节
  • 批准号:
    7275351
  • 财政年份:
    2002
  • 资助金额:
    $ 22.35万
  • 项目类别:
Stress response and HPA regulation in cocaine addiction
可卡因成瘾中的应激反应和 HPA 调节
  • 批准号:
    7106361
  • 财政年份:
    2002
  • 资助金额:
    $ 22.35万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 22.35万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 22.35万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了